Another decent quarter for company..
Though sales growth was missing, company did well to maintain the profitability momentum of previous quarter..
With half yearly EPS of 15 rupees & facilities back in compliance & 5 USFDA approvals in last three months which will eventually bring sales growth gives more power to its current rally.
At current price of Rs 400 & MCAP of 6400 Crores Jubilant looks undervalued.
A minimum PE of 20 ( though i believe even 25 is possible) with an expected yearly EPS of 30-32 gives a nice upside potential for 600-700 with limited downside..
| Subscribe To Our Free Newsletter |
